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Abstract
Introduction: Predictive survival modelling offers systematic tools for clinical decision-making and indi-
vidualized tailoring of treatment strategies to improve patient outcomes while reducing overall healthcare
costs. In 2015, a number of machine learning and statistical models were benchmarked in the DREAM 9.5
Prostate Cancer Challenge, based on open clinical trial data for metastatic castration resistant prostate can-
cer (mCRPC). However, applying these models into clinical practice poses a practical challenge due to the
inclusion of a large number of model variables, some of which are not routinely monitored or are expensive
to measure.
Objectives: To develop cost-specified variable selection algorithms for constructing cost-effective prognostic
models of overall survival that still preserve sufficient model performance for clinical decision making.
Methods: Penalized Cox regression models were used for the survival prediction. For the variable selection,
we implemented two algorithms: (i) LASSO regularization approach; and (ii) a greedy cost-specified variable
selection algorithm. The models were compared in three cohorts of mCRPC patients from randomized
clinical trials (RCT), as well as in a real-world cohort (RWC) of advanced prostate cancer patients treated
at the Turku University Hospital. Hospital laboratory expenses were utilized as a reference for computing
the costs of introducing new variables into the models.
Results: Compared to measuring the full set of clinical variables, economic costs could be reduced by half
without a significant loss of model performance. The greedy algorithm outperformed the LASSO-based
variable selection with the lowest tested budgets. The overall top performance was higher with the LASSO
algorithm.
Conclusion: The cost-specified variable selection offers significant budget optimization capability for the
real-world survival prediction without compromising the predictive power of the model.
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1. Introduction
Prostate cancer is among the most commonly diagnosed types of cancer in men [1]. The survival time
with the disease is highly dependent on its stage and grade at the time of diagnosis. Mortality due to low
grade prostate cancer can be even lower than due to competing causes of death [2], whereas the median
survival time of patients with newly diagnosed metastases is only 42 months [3]. Due to the aging population
in many countries, the incidence and costs of prostate cancer are expected to increase significantly in the
future [4, 5]. There is therefore a critical challenge to develop cost-effective procedures for prostate cancer
management in order to minimize the burden on public health expenditure.
Several prognostic models have been developed for the survival prediction of patients with metastatic
castration-resistant prostate cancer (mCRPC) [6, 7, 8, 9]. In the DREAM (Dialogue for Reverse Engineer-
ing Assessments and Methods) 9.5 mCRPC Challenge that was organized in 2015, 50 international teams
developed competing models for overall survival prediction. The top performing model (ePCR; ensemble-
based Penalized Cox Regression) significantly outperformed the competing models in independent validation
[10]. Meta-analysis of the Challenge models supported the use of Cox regression model family coupled with
regularization as the state of the art in survival prediction for patients with advanced prostate cancer [10, 11].
The prognostic models have conventionally been developed based on data from clinical trials where it is
often possible to conduct a large number of laboratory tests. This may limit the usefulness of the models
in clinical practice. For instance, the winning model of the DREAM competition takes as input 101 clinical
variables ([10], supplementary appendix). Many of them are related to medical history and their extraction
can be automated, but there are over 40 variables requiring laboratory tests or other rather expensive
procedures such as imaging. Performing all required tests can incur a significant economic cost.
In order to develop cost effective prognostic models, one should favor approaches that require as few
clinical variables as possible, while maintaining predictive performance. This task is closely related to feature
selection (variable selection) that is well known in the field of machine learning [12]. Variable selection can
serve a variety of purposes: models with a smaller number of variables are easier to interpret, more economic
and faster to use, and may generalize better to new data. Varying approaches to variable selection have been
explored when developing models for prostate cancer. In the Halabi model [9] 22 candidate variables were
∗Corresponding author.
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considered, of which 8 were included in the final model. In the ePCR model [10] some candidate variables
were discarded due to being redundant, skewed or clinically insignificant according to expert evaluation.
Such variables included clinical trial adverse effect variables, e.g. eye disorders. Model regularization was
also used. Another model tested in the DREAM Challenge used survival forest and LASSO-based variable
selection procedures [13]. However, none of the studies analyzed or proposed methods for minimizing the
total economic cost of the variables required for applying the models in clinical settings.
The main contribution of this work is the development of cost-specified group-wise variable selection
methods that are widely applicable to survival predictions based on patient hospital data generally available
in clinical practice. The novel methods are applied here to patient cohorts of clinically significant prostate
cancer, using real cost information from Finnish university hospitals. The results indicate that the approach
enables significant saving of economic costs in a real-world settings, and yet high enough prediction accuracy
for clinical applications. Four patient cohorts are included in the experiments: three originating from
randomized clinical trials and one consisting of patients treated at the Turku University Hospital. Two
variable selection methods are implemented and tested, one being a cost-specified greedy algorithm, and the
other based on LASSO regularization. The methods are evaluated in two ways: by using cross-validation
and by using different training and test cohorts. Experiments show that greedy selection gives better results
when the allowed budget is so low that only a few variables are selected. On the other hand, the peak model
performance with LASSO selection is higher in all cross-validation tests. Similar observations are made in
tests with different training and test cohorts, although LASSO selection does not always outperform the
greedy method even with a large budget.
2. Materials and methods
Penalized Cox regression [14] has previously been successfully applied to the survival prediction of pa-
tients with prostate cancer. For instance, the models by Halabi et al. [7, 9] and the top-performing model
of the DREAM competition [10] were based on the Cox proportional hazards model coupled with regu-
larization. Therefore, we also base our approach on penalized Cox regression. Three different types of
penalization terms for the model coefficients are commonly used in order to prevent over-fitting the Cox
model, L1 (LASSO), L2 (ridge regression), or their sum (elastic net) [15]. We only considered the former
two possibilities in the variable selection.
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2.1. Problem setting
In medical care, clinical laboratory tests are typically ordered as a package (group). For example, a
standard blood test package at the Helsinki University Hospital laboratory contains nine measurements
that are useful for characterizing the patient. This includes, for example, hemoglobin and counts of white
and red blood cells and platelets. For the price of the laboratory test package one gets the results of all its
measurements. Some measurements appear in more than one package.
Let the set of all available variables be F . A package of clinical tests is also called a group of variables
Gi and can be specified by listing all its variables. Hence, Gi ⊆ F for all i ∈ {1, 2, ..., ng}, where ng is the
number of groups. To simplify the notation, individual measurements not belonging to any package are
represented as groups containing one variable. It can then be assumed that all variables belong to some
group, i.e. ∪ngi=1Gi = F . On the other hand, a variable may belong to several groups. The price of a group
Gi is denoted by ci.
The variable groups that are included in a model can be specified by listing the corresponding group
indices I. Thus, I ⊆ {1, 2, ..., ng}. It is also allowed to include a group partially. Excluding variables of
a group does not reduce cost but, due to the possibility of overfitting, it may improve model performance.
The selected variables of group Gi are denoted by si ⊆ Gi and the set of all selected variables by S = ∪i∈Isi.
The total cost of the selected variables is C =
∑
i∈I ci.
For given input data d, the performance of a model M is represented as a score function score(M,d),
with a higher score indicating a better model. When comparing models that only differ due to including
different variables, one may also consider the score to be a function of the selected variables, score(S, d).
If a maximum budget B for making measurements is given, the problem is to maximize the performance
score(S, d) while respecting the budget constraint, i.e. C ≤ B.
2.2. Cost-specified variable selection
The budget can be considered as a hard constraint on the set of selected variables, meaning that no
violations of the constraint are allowed. It is difficult to enforce directly, because non-convexity and non-
continuity makes the optimization NP-hard [16]. A popular way to select variables for Cox models is to
introduce an L1-norm constraint on the model, that can be considered as a convex and continuous approx-
imation of the budget constraint. Using the Lagrange method, the L1-norm constraint can be transformed
to a so-called LASSO penalty function, a soft constraint whose effect is controlled by a penalty parameter.
With a high enough amount of penalization, some of the model coefficients get a zero value. The corre-
sponding variables can be removed. By varying the amount of penalization one can select different sets
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of variables. Because the method does not take prices into account, price is computed afterwards using a
heuristic. The heuristic starts with an empty variable set and adds variable groups sequentially. At each
step the group Gi with the minimal cost per new variable is added. New variable means a variable that
has not been already added and is in the target set S and the candidate variable group Gi. The process is
continued until all variables of S have been included.
Using the LASSO penalty for variable selection has a side effect of also penalizing the coefficients of the
useful variables that are selected. While this side effect is sometimes beneficial, as regularized models work
better with noisy data, enforcing small budget constraints requires so strong regularization that it causes
the Cox model to underfit (see the end of the supplementary appendix for a more detailed description
and an example). Therefore, we propose an alternative technique that avoids the side effect, namely a
greedy budget-constrained Cox regression (Greedy Cox) algorithm, that enforces the hard budget constraint
directly. The algorithm can be seen as a variant of the Group-Wise Nested Forward Selection method
proposed by Paclík et al. [17], though the selection criterion is not exactly the same, and their work did
not concern Cox regression or survival analysis. The basic idea of the algorithm is to sequentially select
the group of variables that gives, together with all variables that have been selected earlier, the best cross-
validated prediction performance. This is locally optimal when the only allowed operation is the addition of
a single group of variables. However, some variables of a group may not have a positive effect on prediction
performance. The method is therefore further refined by selecting variables within the groups. This inner
selection is similar to the group selection but operates on individual variables instead of groups, and the
variables are restricted to those of the currently considered group. The variable selection process is stopped
when there are no variable groups that fit within the remaining budget and improve prediction performance.
We chose to utilize L2 penalization in the models fitted in Greedy Cox, because when testing elastic net
combining L1 and L2 in a similar setting [10], models close to using only L2 were found to be optimal.
The pseudocode for selecting the next group and a subset of its variables is given in Algorithm 1. The
algorithm uses the function cv_score to compute cross-validated (3-fold) estimates of model performance.
To compute such an estimate, the function requires the n× d matrix X of all values of the clinical variables
of the patients, the times and types of events (y, δ) and the allowed variable set as an input. The entire
variable selection process starts by initializing an empty set of selected variables. The remaining budget is
set to the total budget because no groups have yet been selected. After the initialization Algorithm 1 is
called repeatedly. After selecting each group the remaining budget and selected variables and groups are
updated. When there are no variables available that fit within the budget and improve model performance,
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the algorithm returns an empty set of variables, and the selection process is stopped.
Several alternatives are available for fitting the Cox models. Goeman [18] developed a method for LASSO
models, and extensions to elastic net penalty were also outlined. The method uses both gradient descent
and the Newton-Raphson algorithm. An algorithm by Simon et al. [19] is based on coordinatewise descent
and was very fast in their tests. Wu [20] adapted least-angle regression to Cox models. Any method for
fitting L1- and L2-penalized models is suitable for our purposes provided that the running time is not too
high. The importance of running time results from both methods fitting a large number of models. In
particular, in the greedy method every call of the function cv_score fits three models due to using 3-fold
cross-validation.
Data: Values of variables X, Survival (y, δ), Remaining budget b, Variable groups G, Group prices c,
Selected variables S, Selected group indices I
Result: The index i of the best group to be added to I and the variables G′i selected from Gi
orig_score := best_score := cv_score(X, (y, δ), S)
i, G′i := null, ∅
I ′ := {j|cj ≤ b ∧ j /∈ I}
for j ∈ I ′ do // Iterate over groups
Fnew := Gj \ S // Unselected variables of the current group
group_score, selected_variables, selection_finished := orig_score, ∅, False
while not selection_finished do // Find the best subset of variables
S′ := S ∪ selected_variables
best_variable_score, best_variable := group_score, null
for f ∈ Fnew do
variable_score := cv_score(X, (y, δ), S′ ∪ {f})
if variable_score > best_variable_score then
best_variable_score, best_variable := variable_score, f
if best_variable 6= null then
group_score, selected_variables :=
best_variable_score, selected_variables ∪ {best_variable}
else
selection_finished := True
if group_score > best_score then
best_score, i, G′i := group_score, j, selected_variables
return i, G′i
Algorithm 1: Selecting the next group and its variables in the Greedy Cox algorithm. The remaining
budget b is the total budget minus the price of the already selected groups I.
2.3. Model evaluation
Concordance index (C-index) [21] is selected as the primary measure of model performance, i.e. as
the performance score function of Section 2.1. It is a measure of how well the order of modeled risks
corresponds to the order of observed survival times. C-index has been commonly used in survival analysis
[22, 23, 24, 25], including in the DREAM competition [10] (supplementary appendix). Although there
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are several estimators for C-index with censored data [25], we limit to the version used in the DREAM
competition: survConcordance function in the R package survival.
Cross-validation is used in model evaluation as follows. The final reported sets of variables are obtained
by applying the selection algorithms on all data that are available for the studied patient cohort. In addition
to the variable sets, estimates of model performance are required. For this purpose variable selection with
five-fold cross-validation is repeated 50 times, giving a total of 250 sequences of variable sets. Each sequence
contains all variable sets that were selected during a single run of a selection algorithm. The performance
scores are computed during the cross-validation using the proper test sets. Finally, the results of the cross-
validation are linked to the final variable sets (that were obtained using all data) by price. For a given
variable set S this means that the last variable sets not exceeding the cost of S are selected from all 250
sequences and the corresponding 250 performance measures are averaged. Note that when using Greedy
Cox, cross-validation is also used in the variable selection process: when considering a given cross-validation
fold, the training data are further divided into cross-validation folds for the variable selection. The test fold
is never included in the variable selection. This scheme is known as nested cross-validation [26].
In cross-validation tests the patient groups in the training and test sets tend to be highly similar because
they are selected from the same patient cohort. This may lead to an optimistic bias in model evaluation.
Therefore, further tests are done where the training and test cohorts originate from independent sources.
We include four patient cohorts and consider all 12 pairs of training and test cohort where the cohorts are
different.
2.4. Patient cohorts
Four patient cohorts were included, three of them originating from randomized clinical trials (RCT
cohorts) included in the Prostate Cancer Challenge (PCC-DREAM), hosted by Project Data Sphere (PDS,
https://www.projectdatasphere.org/), a broad-access research platform that collects and curates patient-
level data from completed, phase III cancer clinical trials. The fourth group (real-world cohort, RWC)
consists of patients treated at the Turku University Hospital according to the clinical recommendations.
The patient registry data for the RWC cohort were provided by the Turku University Hospital Centre for
Clinical Informatics and were processed as before [27]. A notification of the registry-based study design was
made to the Office of the Data Protection Ombudsman according to the appropriate legislation, and the data
gathering and analysis was performed with the permission of the hospital district (approval T287/2016).
The patients of RWC were selected based on castration resistance [27].
The patient cohorts are summarized in Table 1. Only patients that received the standard treatment
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(docetaxel and prednisone) were included in the three RCT cohorts. The ASCENT and MAINSAIL studies
were terminated early due to the novel treatment not being beneficial in comparison to the standard treat-
ment. The short follow-up times were reflected in mortality: less than 30 % of patients died during these
trials, compared to over 70 % in the VENICE and RW cohorts.
The baseline patient characteristics for the RCT cohorts can be found in the respective publications
[28, 29, 30]. In the RW cohort the median age of the patients was 76.3 years (first and third quartiles 70.1
and 82.6 years) in the beginning of the observation period, i.e. when their disease was first diagnosed as
castration resistant. The dates of diagnosis ranged from April 2002 to October 2016. The median values
of clinical variables were as follows: PSA 38.5 µg/l, HB 12.6 g/dl and alkaline phosphatase (ALP) 85 U/l.
The median of the observed values of LDH was 193.5 U/l but the observation was missing for almost 90 %
of the patients. Compared to the RCT cohorts, the patients in the RW cohort were older and their PSA
and ALP values were lower. Information about metastases and the patient performance status (ECOG_C)
were missing for most patients.
Table 1: Patient cohorts included in this study. The columns T25%/median/75% give the quartiles of days to event (death or
censoring). *A data matrix collected and imputed during the DREAM competition was used. **Turku University Hospital.
Name Abbr. Origin Patients T25% Tmedian T75% Tmax % dead
ASCENT ASC RCT[28] * 476 259 357 482 796 29.0
VENICE VEN RCT[29] * 598 392 643 902 1594 72.4
MAINSAIL MAI RCT[30] * 526 194 279 399 750 17.5
RW cohort RWC TYKS [27] ** 581 128 330 702 4188 75.7
The survival curves for all four cohorts are shown in Figure 1. In the early follow-up survival is similar
in all three RCT cohorts, whereas in the RW cohort early mortality is higher. This is reflected also in the
median times to event in Table 1: although a similar number of deaths occurred in VEN and RWC, the
median time to event is much higher in VEN. The short follow-up times in the ASCENT and MAINSAIL
cohorts are also apparent. In the RW cohort, survival (or censoring) times are counted starting from the
first instance mentioning castration resistance in the patient records. The PCA plot in Figure 1 indicates a
difference in the baseline patient characteristics between RWC and the RCT cohorts.
As potential model variables we started with the 101 variables of the original ePCR model (Supple-
mentary Data, Table 1). Prices of various clinical examinations were provided by the Helsinki University
Hospital. Variables that can be automatically extracted from patient records, such as medical history, were
assumed to be cost-free. There were 16 variables without a known cost, including information about metas-
tases. Those variables were ignored, leaving 85 potential variables. The variable groups, their variables and
prices are shown in Table 2.
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Figure 1: (a) Overall survival in the four cohorts. Circles indicate the censoring times. (b) PCA plot of the numeric variables
of the four cohorts. The RCT cohorts appear to be similar to each other, but the RW cohort differs from them.
3. Results
The following questions were considered when conducting the cost vs. prediction performance trade-off
evaluations:
1. Can variable set cost be reduced with little or no loss of model performance?
2. Which of the variable selection methods is optimal with different budgets?
3. Do the models give satisfactory results outside their training cohorts?
Cross-validation tests give answers to the first two questions. Tests where the training and test cohort
originate from independent sources answer the last question while also providing further information about
the usefulness of the estimated models. With the four patient cohorts there are 16 different pairs of training
and test cohort: four where the cohorts are the same and 12 where they are different. All these pairs were
considered by training a model on one cohort and evaluating it on another cohort. Cross-validation was
used in cases where the training and test cohorts are the same. Several variables were missing for most
of the patients in the RW cohort, including lactate dehydrogenase and aspartate aminotransferase, which
have previously been identified as important predictive variables [10], resulting in differences in the selected
variable sets between the RW and RCT cohorts.
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Table 2: Variable groups and their prices. The prices are standardized so that the PSA measurement gets the reference cost of
100. The groups correspond to laboratory test packages available at the Helsinki University Hospital. Only variables considered
for inclusion are shown. Non-abbreviated names of the variables are given in Supplementary Appendix, Table 1.
Group Model variables Price
B-PVKT HB, HEMAT, RBC, WBC, PLT 40
B-PVK+Ne Same as in B-PVKT except PLT 60
B-PVK+TKD B-PVKT + LYMperLEU, MONOperLEU, NEU, POT, MONO, BASOper-
LEU, EOSperLEU, NEUperLEU
90
B-Hb HB 50
cB-Het-Ion NA. 100
Pt-GFReEPI CCRC 20
P-LD LDH 20
P-ASAT AST 20
P-ALB ALB 20
P-AFOS ALP 20
P-PSA PSA 100
P-Krea CREAT 20
Pt-Krea-Cl CREACL 70
B-Lymf LYM 90
P-Pi PHOS 20
P-Ca CA 20
P-Alat ALT 20
S-Prot TPRO 20
B-PNH-La WBC 4200
B-Eos EOS 90
S-Testo TESTO 330
P-Gluk GLU 20
P-Mg MG 20
P-Bil TBILI 20
Free variables Medical history, age, race/region, performance status (ECOG_C), medicines
in use
0
3.1. Implementation
The variable selection algorithms described in Section 2.2 were implemented in Python language, version
3.5.2, and the glmnet package1 was used for model fitting. Concordance indices were computed with the
lifelines package. Variable sets were determined separately for the four data sets using both algorithms.
In RWC, missing values were filled in using median imputation, which has previously been tested to give
satisfactory results [27]. We also tested k-Nearest Neighbor (kNN) imputation before starting the variable
selection tests but it did not improve model performance.
3.2. Test results
Figure 2 shows the C-index scores obtained in the four cohorts using the two variable selection algorithms
with various budgets, both for the cross-validation and independent training-test cohort evaluations. There
1https://web.stanford.edu/~hastie/glmnet_python/
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were clear differences between the cohorts in the achieved model performance. The order of survival times
was predicted best in the RW cohort, with C-index up to 0.721, while in the VENICE cohort C-index was
only 0.653. In the ASCENT and MAINSAIL cohorts the C-indices were up to 0.680 and 0.700, respectively.
The reasons for the differences between the RCT cohorts are not known but the good results in the RW
cohort may be explained by there not being stringent inclusion criteria in this cohort, making the patient
population heterogeneous. In fact, PSA measurement alone allowed a model fitted to the RW cohort to
achieve a C-index that was similar to the best tested models in the VENICE cohort.
3.2.1. Cross-validation results
In cross-validation tests the peak C-index of LASSO selection was always better than that of Greedy
Cox but with low budgets Greedy Cox often achieved better results than LASSO. The results of LASSO
selection also deteriorated with the greatest budgets while those of Greedy Cox remained stable. A possible
reason is that in Greedy Cox the amount of model penalization is fixed while in LASSO selection high-cost
variable sets are obtained by reducing the penalization.
With relatively low budgets slightly increasing the budget occasionally worsened model performance
when using Greedy Cox. The reason is that the larger budget was spent on the first selected variable group,
after which only cost-free variables could be selected. With a slightly lower budget, a less expensive variable
group had to be selected first, leaving enough budget to select another inexpensive but non-free group.
Table 3 shows the variables selected for the RW cohort by the two algorithms and the achieved C-indices.
An unlimited budget was used in Greedy Cox. The table shows the variables selected in each step of the
algorithm. The results do not fully correspond to what one would get by limiting the budget, but it was
verified that the differences are minor for the budgets shown in Table 3. The variable sets selected by the two
methods are similar during the initial steps, after which the selection paths diverge. Of previously known
prognostic variables lactate dehydrogenase (LDH) [9, 10] was not included, likely because it was missing for
over 80 % of patients in RWC.
Table 3: Variables selected in the RW cohort in one representative run of the two algorithms. Variables selected after achieving
peak performance score are not shown. An unlimited budget was used in Greedy Cox. Prices are standardized so that PSA
measurement gets a reference cost of 100.
Added (LASSO) Cost C-index Added (Greedy) Cost C-index
PSA 100 0.644 PSA 100 0.656
HB 140 0.675 HB, WBC, LYMperLEU,
NEUperLEU
190 0.703
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ALP 160 0.693 ALP 210 0.714
AGEGRP2 160 0.693 LYMPHAD. 210 0.714
NA. 260 0.711 MHRENAL 210 0.714
LYMPHAD., CEREBACC 260 0.711 CHF 210 0.714
CREAT 280 0.713 MHGASTRO 210 0.714
CA 300 0.716 MG 230 0.713
PROSTATECTOMY 300 0.716 CA 250 0.714
MHRENAL 300 0.716 MHRESP 250 0.714
MHRESP 300 0.716 CREAT 270 0.714
COPD 300 0.716 LDH 290 0.714
HEMAT 300 0.716 MHBLOOD 290 0.714
PHOS 320 0.719 MHCARD 290 0.714
AST 340 0.720 MHINJURY 290 0.714
BILAT. ORCHID. 340 0.720 CCRC 310 0.713
POT 430 0.721
CHF, MHGASTRO 430 0.721
RBC 430 0.721
WBC 430 0.721
HMG_COA_REDUCT 430 0.721
ANALGESICS 430 0.721
ACE_INHIBITORS 430 0.721
3.2.2. Tests with different training and test cohorts
When different cohorts were used for model fitting and evaluation, Greedy Cox still often outperformed
LASSO selection with low budgets. The peak performance of LASSO was again in many cases better than
that of Greedy Cox, but there were also cases where Greedy Cox outperformed LASSO or their scores
were very similar. Figure 2 also gives a coarse indication of how much model performance is lost when the
training and test sets are not subsets of the same cohort, which is the more typical use case in practice.
The cross-validated C-index in the MAINSAIL cohort with LASSO selection is clearly higher (0.70) than
what is achieved by models fitted to the other cohorts (0.65-0.68). Greedy Cox applied on ASCENT does
achieve a high C-index (slightly over 0.70) with a very low budget. However, in a real predictive setting
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one would not know the C-index that will be achieved in the new cohort and the budget would have to be
chosen based on, for example, the cross-validation results. Then, a greater budget would be chosen and the
resulting model would perform much worse when evaluated in the MAINSAIL cohort, C-index well below
0.65. Except for the poor fit to MAINSAIL, a model fitted to the VENICE cohort performs well in the
other cohorts. Models fitted to the RW cohort have somewhat similar predictive performance as those fitted
to VENICE. Models fitted to MAINSAIL and ASCENT are not able to predict the survival times of the
patients well for the RW and VENICE cohorts. The worse performance of models fitted to ASCENT or
MAINSAIL compared to VENICE and RW may be related to the fact that there were relatively few deaths
in the former two trials. In the RW cohort many observations are missing and, as noted before (Figure 1),
the baseline patient characteristics differ between the RCT and RW cohorts.
4. Discussion
We developed tools for constructing survival models that incorporate both the prognostic value and
real-life clinical cost of the available variables. The tools were applied to cohorts of prostate cancer patients,
and considerable cost savings were possible. In particular, maximal prediction performance was obtained
with variable sets whose total cost was 2-4 times the cost of PSA measurement. Additional variables
had a negative effect on prediction performance when using LASSO penalization because the amount of
penalization had to be reduced to include more variables. The number of variables in the best models was
usually 10-15 and at most 19 when the full candidate set contained 85 variables with a known cost.
The variables selected by the two algorithms and for different cohorts (Supplementary Appendix, Section
4.2) were surprisingly dissimilar. Some of the differences are explained by data availability. For instance,
lactate dehydrogenase (LDH) was selected in all RCT cohorts when the budget was sufficient for achieving
maximal model performance, but in the RW cohort it was not available for most patients. However, even
in the RCT cohorts LDH was the only variable that was always selected. When ranking the variables
in terms of how often they were selected in the four cohorts by the two algorithms (8 test cases), LDH,
hemoglobin (HB), alkaline phosphatase (ALP), history of congestive heart failure (CHF) and PSA ranked
highest. Except for LDH and CHF, they were selected in the RW cohort by both algorithms. They were also
selected in the RCT cohorts in 2-3 of 6 test cases. Apart from CHF these variables were also identified as
important in the DREAM competition [10] (supplementary appendix). On the other hand, several variables
that were important in the competition were rarely selected by the algorithms considered in this work:
aspartate aminotransferase (AST), red blood cell count (RBC), albumin (ALB) and patient performance
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status (ECOG_C). AST was selected in the RW cohort by both algorithms and in MAINSAIL cohort by
Greedy Cox. ALB was selected in the MAINSAIL cohort by both algorithms but not in any other cohort.
ECOG_C was selected only in the VENICE cohort by LASSO. RBC was not selected in any cohort by
either algorithm.
In cross-validation tests greedy selection outperformed LASSO with low budgets but when a larger budget
was allowed, LASSO was better. A similar observation has been made earlier in a different application
domain [31] and has been explained by too much penalization when selecting only a few variables using
LASSO [32]. When the training and test cohorts were different, the results were mixed between the variable
selection methods. Overall, Greedy Cox was better when only a few variables were included in the models
while LASSO was very competitive with larger budgets.
Further developments on both the greedy approach and penalized models are possible. For instance, in
the greedy selection it might be beneficial to remove variables that have become redundant as a result of
adding other variables. The penalized approach considered in this work, LASSO, does not take the groups
of variables and their prices into account; the cost of a variable set was computed after the selection process.
With larger budgets this gave rather good results, but incorporating the cost in the model as an additional
penalization term might further improve the results, especially with lower budgets.
Limitations of the study
The study considered mortality due to all causes. Therefore the variables selected by the algorithms
may contain variables that are not related specifically to prostate cancer. Even in the initial set of variables
there was a scarcity of actual biomarkers of prostate cancer. While more comprehensive patient information
would be preferable, the lack of biomarkers beyond PSA corresponds to what is available from the current
clinical management of prostate cancer patients.
Metastasis status was excluded from variable selection due to missing price information and questionable
availability in the RW data set. While this is a significant omission, one may note that in the 2015 DREAM
competition information about any particular metastasis site was included in the models of less than 20 % of
the teams, although the winning model did include several locations of metastases (see [27], Supplementary
appendix). Unlike in the RCTs dealing with mCRPC, in the RW cohort there can be patients without any
metastases, making the availability of this information potentially more important. Cost-specified variable
selection should be repeated when the prices of additional variables become available. The proposed approach
and the selected variables warrant further studies in other patient cohorts, both in prostate cancer and other
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related cancer types, to confirm their prostate cancer-specificity, and applicability of the approach to other
cancer types.
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Summary table
What was already known on the topic
• Several models are available for the survival prediction of patients with prostate cancer
• Variable selection methods have been used when developing the models
• Variable set cost has not been an explicit goal in variable selection
What this study added to our knowledge
• Two methods were developed for selecting cost-effective sets of variables in survival prediction
• The methods offer significant cost reduction potential in all tested cohorts with minor or no loss of
model performance
• The results of variable selection are sensitive to differences in algorithms and data sets
• With very low budgets Greedy Cox tends to produce better models than LASSO selection
• With large budgets LASSO selection is very competitive
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Figure 2: C-index scores achieved by the two variable selection algorithms in four cohorts. The rows correspond to the training
cohorts and the columns to the test cohorts. The plots on the diagonal show cross-validation results where the training and
test sets are non-overlapping subsets of the same cohort of patients. 50 budgets were considered when selecting variables using
Greedy Cox, except in the cross-validation tests where only 8 budgets were tested due to high execution time. In tests involving
the RW cohort, only variables that were available for at least 60 % of the patients were included as potential model variables.
In other cases all variables with a known price were included in the analysis.
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